Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Consumer self-care products provider Perrigo Company plc (NYSE: PRGO) announced that it has shipped Opill to major retailers and pharmacies and will be available on shelves across the country and online later this month. The first oral contraceptive approved for OTC use by any age group in July 2023 is Opill®; it is a daily birth control pill that does not require a prescription in the United States. Now, Opill® can be pre-ordered from some online retailers, and it is expected to appear on leading stores’ shelves in weeks to come. These options include one-month and three-month packs of Opill® with recommended retail prices (RRP) of $19.99 and $49.99, respectively.
On Thursday, early the FDA said an over-the-counter birth control pill could now be sold without a prescription,” reports AP News opens in a new tab or window which further adds that this pill contains norgestrel as an active substance. According to him or her, the approval allows women who are looking for contraceptive pills without any prescription requirements, not only at drugstores but also at other retail outlets such as supermarkets or even online marketplaces. The announcement made by the agency indicates that “Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.”
The U.S. Food and Drug Administration (FDA) has just granted approval to NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets), according to Mayne Pharma press release for pregnancy prevention purposes. The above-mentioned product is unique because no other contraceptive containing E4 exists; henceforth, E4 should no longer be considered a synthetic estrogen since it has been derived from plants. Nearly 10 million women in the United States use short-acting combination contraceptives (estrogen and progestin). These contain over 99% ethinyl estradiol, a synthetic estrogen that binds to all estrogen receptors in the body.
The efforts made by governments to reduce population growth in various nations are raising women's understanding of family planning and contraception in both urban and rural settings. In industrialized markets, the use of oral contraceptives has also increased due to the rising occurrence of unintended pregnancies. The population is expanding at a rapid rate, particularly in Asian countries, which is having a micro-level impact on the socio-economic balance. Public and private players are cooperating to manage the population growth, and this is anticipated to have a positive effect on sex education and contraception use in the years to come. The revenue from the contraceptive pills market is predicted to increase as a result throughout the forecast period. Thus, this factor is driving the market CAGR for contraceptive pills.
Additionally, the increased use of creative marketing methods is the primary factor driving the worldwide contraceptive pills market growth. The industry is expanding because vendors are investing a lot of money in marketing and promotion. Major brands of contraceptives have boosted their marketing spending to keep their top spots in the market. Several PR initiatives are being carried out to pique women's interest in trying out female contraceptives like birth control pills. Print advertisements and events that attract women from various demographics are two other marketing strategies. Users' desire for birth control tablets is anticipated to rise as a result. Vendors can spread awareness of their selection of items by engaging in substantial marketing. Moreover, short-form video ads raise awareness of contraceptive pills. Users are encouraged to discuss birth control with their doctors, which prompts them to experiment with various brands. These programmes boost birth control pill sales, which fuels the market's expansion for contraceptive pills.
Furthermore, the demand for contraceptive pills is significantly influenced by the rising number of unwanted pregnancies, which is helping the industry expand. For instance, 1.4 million unplanned pregnancies occurred in 115 low- and middle-income countries, according to a March 2021 update by the UN Population Fund. As a result, these numbers show an increase in demand for contraceptive tablets globally, which is helping the contraceptive pills industry to grow.
However, several actions done by governments around the world are also anticipated to boost market expansion for contraceptive pills. For instance, the Spanish government reportedly amended the law governing sexual and reproductive health and the voluntary termination of pregnancy in May 2022, according to the Council of Ministers of Spain. There have been new initiatives in the areas of reproductive violence, menstrual health, pregnancy, childbirth, and sexual education and contraception. Also, it was said that all pharmacies must carry the morning-after pill and that it will be made freely available at health centers and upcoming public facilities dedicated to sexual and reproductive rights. Thus, it is anticipated that this aspect will accelerate contraceptive pills market revenue globally.
The Contraceptive Pills Market segmentation, based on drug class, includes Monophasic, Triphasic and Others. The triphasic segment held the mrajority share in 2022 in the Contraceptive Pills Market data. The formulation of triphasic contraceptive tablets, which include three separate hormone doses, alters roughly every week throughout your cycle. It has been discovered that triphasic tablets can lower the frequency of headaches, anxiety, and breast tenderness without changing blood pressure or weight. Research suggests that triphasic medications may have a greater chance than monophasic ones of affecting mood symptoms.
The Contraceptive Pills Market segmentation, based on combination pills, includes Monophasic and Multiphasic Pills. The monophasic segment dominated the market growth for contraceptive pills in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The monophasic pill contains estrogen and progestin, which inhibit ovulation and stop the production of a mature egg from the ovaries, respectively, to prevent conception. Moreover, it thickens the cervical mucus, generating a block that prevents sperm from passing through. It causes the uterine lining to thin, which makes implantation of the egg challenging.
Figure 2: Contraceptive Pills Market, by Combination Pills, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights for contraceptive pills into North America, Europe, Asia-Pacific and Rest of the World. Asia Pacific contraceptive pills market accounted for USD 9.6 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period due to increased awareness and government population control activities implemented through commercials and campaigns. The market for contraception is expanding as teens in the region become more aware of unsafe sex and unintended pregnancies. In Asia, there are about 41% of married teens who use contraception pills.
Further, the major countries studied in the market report for contraceptive pills are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: CONTRACEPTIVE PILLS MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
North America contraceptive pills market accounts for the second-largest market share attributable to the region's high level of awareness regarding birth control pills and the quick growth of the healthcare infrastructure. For instance, the birth control pill is the most frequently prescribed method of birth control in the United States, and 25% of women aged 15 to 44 who are currently using contraception reported using the pill as their preferred method. The combined hormonal pill containing estrogen and progesterone was discovered to be the most frequently prescribed pill. Moreover, US contraceptive pills market held the largest market share, and the Canada contraceptive pills market was the fastest growing market in the region.
Asia Pacific contraceptive pills Market is expected to grow at the fastest CAGR from 2022 to 2030 due to the government's population control activities and the rise of numerous non-profit groups in the area that seek to increase awareness of various birth-control options. The introduction of awareness campaigns by governmental organisations and other regulatory bodies to boost the use of contraceptive pills in home healthcare fuels market expansion. Further, the UK contraceptive pills market held the largest market share, and the Germany contraceptive pills market was the fastest growing market in the region.
Major market players are spending a lot of money on R&D to increase their product lines, which will help the contraceptive pills market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the contraceptive pills industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global contraceptive pills industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, contraceptive pills industry has provided medicine with some of the most significant benefits. The contraceptive pills market major player such as Sanofi S.A., Bayer Healthcare, Janssen Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Organon International, Teva Pharmaceuticals, Aurobindo Pharma Limited, Abbvie Inc, Johnson & Johnson and Pfizer Inc.
Jersey City, New Jersey serves as the corporate headquarters for the American pharmaceutical business Organon & Co. Organon focuses on the following major treatment areas: anaesthesia, psychiatry, hormone replacement therapy (HRT), reproductive medicine, and contraception. International markets are served by Organon. In February 2022, Marvelon and Mercilon, combined oral hormonal daily contraceptive tablets, were bought by Organon from Bayer AG for the People's Republic of China, including Hong Kong and Macau, and an agreement was made to purchase these medications in Vietnam.
A London-based pharmaceutical firm called Theramex creates women's health medicines with a focus on menopause, osteoporosis, fertility, and contraception. It was founded in 2018 after Teva Active Pharmaceutical Ingredients acquired some of the assets related to Theramex Labs, a pharmaceutical company with a Monaco address. In January 2020, an undisclosed sum was paid by Theramex, a specialized female pharmaceutical business, for the rights to Zoely, a patented oral contraceptive. With this acquisition, Theramex is able to diversify its product offering and expand its global footprint.
Key Companies in the contraceptive pills market includes
Contraceptive Pills Industry Developments
November 2022: To commercialise a generic version of Slynd Tablets, 4 mg, of Exeltis USA Inc., Lupin Limited stated that their Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, had gained provisional approval from the US FDA.
October 2022: The introduction of Drovelis, an oral contraceptive that combines drospirenone (DRSP) and estradiol (E4], in the UK was announced by Gedeon Richter, a company located in Hungary.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 20.9 billion |
| Market Size 2023 | USD 21.4 billion |
| Market Size 2032 | USD 25.38 billion |
| Compound Annual Growth Rate (CAGR) | Â 2.2% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Class, Combination Pills, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Sanofi S.A., Bayer Healthcare, Janssen Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Organon International, Teva Pharmaceuticals |
| Key Market Opportunities | New product developments |
| Key Market Dynamics | Technological advancement Macro economical and governing factors |
Frequently Asked Questions (FAQ) :
The Contraceptive Pills Market size was valued at USD 20.9 Billion in 2022.
The Contraceptive Pills Market is projected to grow at a CAGR of 2.2% during the forecast period, 2023-2032.
Asia Pacific had the largest share in the global market for contraceptive pills.
The key players in the market for contraceptive pills are Sanofi S.A., Bayer Healthcare, Janssen Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Organon International, Teva Pharmaceuticals.
The triphasic dominated the contraceptive pills market in 2022.
The monophasic had the largest share in the Contraceptive Pills Market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
